Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
about
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaBortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.
P2860
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@ast
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@en
type
label
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@ast
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@en
prefLabel
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@ast
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@en
P1476
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
@en
P2093
Kathleen Colson
Sundar Jagannath
P304
1; discussion 8; suppl 13
P577
2006-05-01T00:00:00Z